Publicacions

Fox EJ, Markowitz C, Applebee A, Montalban X, Wolinsky JS, Belachew S, Fiore D, Pei J, Musch B, Giovannoni G. Ocrelizumab reduces progression of upper extremity impairment in patients with primary progressive multiple sclerosis: Findings from the phase III randomized ORATORIO trial. Mult Scler. 2018 Nov 12. PMID: 30415593

Malhotra S, Villar LM, Costa C, Midaglia L, Cubedo M, Medina S, Fissolo N, Río J, Castilló J, Álvarez-Cermeño JC, Sánchez A, Montalban X, Comabella M. Circulating EZH2-positive T cells are decreased in multiple sclerosis patients. J Neuroinflammation. 2018 Oct 26. PMID: 30367633

Soelberg Sorensen P, Giovannoni G, Montalban X, Thalheim C, Zaratin P, Comi G. The Multiple Sclerosis Care Unit. Mult Scler. 2018 Oct 23. PMID: 30351211

Saposnik G, Montalban X, Selchen D, Terzaghi MA, Bakdache F, Montoya A, Fruns M, Caceres F, Oh J. Therapeutic Inertia in Multiple Sclerosis Care: A Study of Canadian Neurologists. Front Neurol. 2018. PMID: 30319523

Oh J, Vidal-Jordana A, Montalban X. Multiple sclerosis: clinical aspects. Curr Opin Neurol. 2018 Dec. PMID: 30300239

Gil-Varea E, Urcelay E, Vilariño-Güell C, Costa C, Midaglia L, Matesanz F, Rodríguez-Antigüedad A, Oksenberg J, Espino-Paisan L, Dessa Sadovnick A, Saiz A, Villar LM, García-Merino JA, Ramió-Torrentà L, Triviño JC, Quintana E, Robles R, Sánchez-López A, Arroyo R, Alvarez-Cermeño JC, Vidal-Jordana A, Malhotra S, Fissolo N, Montalban X, Comabella M. Exome sequencing study in patients with multiple sclerosis reveals variants associated with disease course. J Neuroinflammation. 2018 Sep 14. PMID: 30217166

Wolinsky JS, Montalban X, Hauser SL, Giovannoni G, Vermersch P, Bernasconi C, Deol-Bhullar G, Garren H, Chin P, Belachew S, Kappos L. Evaluation of no evidence of progression or active disease (NEPAD) in patients with primary progressive multiple sclerosis in the ORATORIO trial. Ann Neurol. 2018 Oct. PMID: 30155979

Bendfeldt K, Taschler B, Gaetano L, Madoerin P, Kuster P, Mueller-Lenke N, Amann M, Vrenken H, Wottschel V, Barkhof F, Borgwardt S, Klöppel S, Wicklein EM, Kappos L, Edan G, Freedman MS, Montalbán X, Hartung HP, Pohl C, Sandbrink R, Sprenger T, Radue EW, Wuerfel J, Nichols TE. MRI-based prediction of conversion from clinically isolated syndrome to clinically definite multiple sclerosis using SVM and lesion geometry. Brain Imaging Behav. 2018 Aug 28. PMID: 30155789

Midaglia L, Gratacòs M, Caronna E, Raguer N, Sastre-Garriga J, Montalban X, Tintoré M. Myasthenia gravis following alemtuzumab therapy for multiple sclerosis. Neurology. 2018 Sep 25. PMID: 30143565

Cohen JA, Comi G, Arnold DL, Bar-Or A, Selmaj KW, Steinman L, Havrdová EK, Cree BA, Montalbán X, Hartung HP, Huang V, Frohna P, Skolnick BE, Kappos L, RADIANCE Trial Investigators.. Efficacy and safety of ozanimod in multiple sclerosis: Dose-blinded extension of a randomized phase II study. Mult Scler. 2018 Jul 25. PMID: 30043658

Saposnik G, Tobler PN, Caceres F, Terzaghi MA, Ruff C, Maurino J, Fruns Quintana M, Oh J, Montalban X, Mamdani M. Usability of an Educational Intervention to Overcome Therapeutic Inertia in Multiple Sclerosis Care. Front Neurol. 2018. PMID: 30042720

Montalban X, Leist TP, Cohen BA, Moses H, Campbell J, Hicking C, Dangond F. Cladribine tablets added to IFN-β in active relapsing MS: The ONWARD study. Neurol Neuroimmunol Neuroinflamm. 2018 Sep. PMID: 30027104

Leussink VI, Montalban X, Hartung HP. Restoring Axonal Function with 4-Aminopyridine: Clinical Efficacy in Multiple Sclerosis and Beyond. CNS Drugs. 2018 Jul 10. PMID: 29992409

Fissolo N, Cervera-Carles L, Villar Guimerans LM, Lleó A, Clarimón J, Drulovic J, Dujmovic I, Voortman M, Khalil M, Gil E, Navarro L, Álvarez-Cermeño JC, Montalban X, Comabella M. Cerebrospinal fluid mitochondrial DNA levels in patients with multiple sclerosis. Mult Scler. 2018 Jul 1. PMID: 29985092

Quintana E, Coll C, Salavedra-Pont J, Muñoz-San Martín M, Robles-Cedeño R, Tomàs-Roig J, Buxó M, Matute-Blanch C, Villar LM, Montalban X, Comabella M, Perkal H, Gich J, Ramió-Torrentà L. Cognitive impairment in early stages of multiple sclerosis is associated with high cerebrospinal fluid levels of chitinase 3-like 1 and neurofilament light chain. Eur J Neurol. 2018 Sep. PMID: 29797629

Mulero P, Midaglia L, Montalban X. Ocrelizumab: a new milestone in multiple sclerosis therapy. Ther Adv Neurol Disord. 2018. PMID: 29774057

Marrie RA, Montalban X. Disease-modifying therapy in multiple sclerosis: Two guidelines (almost) passing in the night. Mult Scler. 2018 Apr. PMID: 29692224

Saposnik G, Montalban X. Therapeutic Inertia in the New Landscape of Multiple Sclerosis Care. Front Neurol. 2018. PMID: 29615967

Miller DH, Lublin FD, Sormani MP, Kappos L, Yaldizli Ö, Freedman MS, Cree BAC, Weiner HL, Lubetzki C, Hartung HP, Montalban X, Uitdehaag BMJ, MacManus DG, Yousry TA, Gandini Wheeler-Kingshott CAM, Li B, Putzki N, Merschhemke M, Häring DA, Wolinsky JS. Brain atrophy and disability worsening in primary progressive multiple sclerosis: insights from the INFORMS study. Ann Clin Transl Neurol. 2018 Mar. PMID: 29560379

Buck D, Andlauer TF, Igl W, Wicklein EM, Mühlau M, Weber F, Köchert K, Pohl C, Arnason B, Comi G, Cook S, Filippi M, Hartung HP, Jeffery D, Kappos L, Barkhof F, Edan G, Freedman MS, Montalbán X, Müller-Myhsok B, Hemmer B, BEYOND and BENEFIT Study Groups.. Effect of HLA-DRB1 alleles and genetic variants on the development of neutralizing antibodies to interferon beta in the BEYOND and BENEFIT trials. Mult Scler. 2018 Mar 1. PMID: 29521573

Parmar K, Stadelmann C, Rocca MA, Langdon D, D'Angelo E, D'Souza M, Burggraaff J, Wegner C, Sastre-Garriga J, Barrantes-Freer A, Dorn J, Uitdehaag BMJ, Montalban X, Wuerfel J, Enzinger C, Rovira A, Tintore M, Filippi M, Kappos L, Sprenger T, MAGNIMS study group.. The role of the cerebellum in multiple sclerosis-150 years after Charcot. Neurosci Biobehav Rev. 2018 Jun. PMID: 29477616

Camara-Lemarroy CR, Castilló J, Sastre-Garriga J, Tintore M, Montalban X. Severe hypertriglyceridemia associated with teriflunomide in a patient with multiple sclerosis: A case report. Mult Scler. 2018 Sep. PMID: 29473796

Arrambide G, Tintore M, Espejo C, Auger C, Castillo M, Río J, Castilló J, Vidal-Jordana A, Galán I, Nos C, Mitjana R, Mulero P, de Barros A, Rodríguez-Acevedo B, Midaglia L, Sastre-Garriga J, Rovira A, Comabella M, Montalban X. The value of oligoclonal bands in the multiple sclerosis diagnostic criteria. Brain. 2018 Apr 1. PMID: 29462277

Matute-Blanch C, Villar LM, Álvarez-Cermeño JC, Rejdak K, Evdoshenko E, Makshakov G, Nazarov V, Lapin S, Midaglia L, Vidal-Jordana A, Drulovic J, García-Merino A, Sánchez-López AJ, Havrdova E, Saiz A, Llufriu S, Alvarez-Lafuente R, Schroeder I, Zettl UK, Galimberti D, Ramió-Torrentà L, Robles R, Quintana E, Hegen H, Deisenhammer F, Río J, Tintoré M, Sánchez A, Montalban X, Comabella M. Neurofilament light chain and oligoclonal bands are prognostic biomarkers in radiologically isolated syndrome. Brain. 2018 Apr 1. PMID: 29452342

Pareto D, Sastre-Garriga J, Alonso J, Galán I, Arévalo MJ, Renom M, Montalban X, Rovira À. Classic Block Design "Pseudo"-Resting-State fMRI Changes After a Neurorehabilitation Program in Patients with Multiple Sclerosis. J Neuroimaging. 2018 May. PMID: 29400912

Alcaide-Leon P, Cybulsky K, Sankar S, Casserly C, Leung G, Hohol M, Selchen D, Montalban X, Bharatha A, Oh J. Quantitative spinal cord MRI in radiologically isolated syndrome. Neurol Neuroimmunol Neuroinflamm. 2018 Mar. PMID: 29359174

Montalban X, Gold R, Thompson AJ, Otero-Romero S, Amato MP, Chandraratna D, Clanet M, Comi G, Derfuss T, Fazekas F, Hartung HP, Havrdova E, Hemmer B, Kappos L, Liblau R, Lubetzki C, Marcus E, Miller DH, Olsson T, Pilling S, Selmaj K, Siva A, Sorensen PS, Sormani MP, Thalheim C, Wiendl H, Zipp F. ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis. Mult Scler. 2018 Feb. PMID: 29353550

Montalban X, Gold R, Thompson AJ, Otero-Romero S, Amato MP, Chandraratna D, Clanet M, Comi G, Derfuss T, Fazekas F, Hartung HP, Havrdova E, Hemmer B, Kappos L, Liblau R, Lubetzki C, Marcus E, Miller DH, Olsson T, Pilling S, Selmaj K, Siva A, Sorensen PS, Sormani MP, Thalheim C, Wiendl H, Zipp F. ECTRIMS/EAN guideline on the pharmacological treatment of people with multiple sclerosis. Eur J Neurol. 2018 Feb. PMID: 29352526

Aymerich FX, Auger C, Alonso J, Alberich M, Sastre-Garriga J, Tintoré M, Montalban X, Rovira A. Cervical Cord Atrophy and Long-Term Disease Progression in Patients with Primary-Progressive Multiple Sclerosis. AJNR Am J Neuroradiol. 2018 Feb. PMID: 29284602

Filippi M, Preziosa P, Meani A, Ciccarelli O, Mesaros S, Rovira A, Frederiksen J, Enzinger C, Barkhof F, Gasperini C, Brownlee W, Drulovic J, Montalban X, Cramer SP, Pichler A, Hagens M, Ruggieri S, Martinelli V, Miszkiel K, Tintorè M, Comi G, Dekker I, Uitdehaag B, Dujmovic-Basuroski I, Rocca MA. Prediction of a multiple sclerosis diagnosis in patients with clinically isolated syndrome using the 2016 MAGNIMS and 2010 McDonald criteria: a retrospective study. Lancet Neurol. 2018 Feb. PMID: 29275979

Thompson AJ, Banwell BL, Barkhof F, Carroll WM, Coetzee T, Comi G, Correale J, Fazekas F, Filippi M, Freedman MS, Fujihara K, Galetta SL, Hartung HP, Kappos L, Lublin FD, Marrie RA, Miller AE, Miller DH, Montalban X, Mowry EM, Sorensen PS, Tintoré M, Traboulsee AL, Trojano M, Uitdehaag BMJ, Vukusic S, Waubant E, Weinshenker BG, Reingold SC, Cohen JA. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018 Feb. PMID: 29275977

Midaglia L, Mora L, Mulero P, Sastre-Garriga J, Montalban X. [Rituximab: its efficacy, effectiveness and safety in the treatment of multiple sclerosis]. Rev Neurol. 2018 Jan 1. PMID: 29251340

Calvo-Barreiro L, Eixarch H, Montalban X, Espejo C. Combined therapies to treat complex diseases: The role of the gut microbiota in multiple sclerosis. Autoimmun Rev. 2018 Feb. PMID: 29191793

Alenda R, Costa-Frossard L, Alvarez-Lafuente R, Espejo C, Rodríguez-Martín E, Sainz de la Maza S, Villarrubia N, Río J, Domínguez-Mozo MI, Montalban X, Álvarez-Cermeño JC, Villar LM. Correction to: Blood lymphocyte subsets identify optimal responders to IFN-beta in MS. J Neurol. 2018 Jan. PMID: 29177546

Malhotra S, Sorosina M, Río J, Peroni S, Midaglia L, Villar LM, Álvarez-Cermeño JC, Schroeder I, Esposito F, Clarelli F, Zettl UK, Lechner-Scott J, Spataro N, Navarro A, Comi G, Montalban X, Martinelli-Boneschi F, Comabella M. NLRP3 polymorphisms and response to interferon-beta in multiple sclerosis patients. Mult Scler. 2018 Oct. PMID: 29117789

Matute-Blanch C, Montalban X, Comabella M. Multiple sclerosis, and other demyelinating and autoimmune inflammatory diseases of the central nervous system. Handb Clin Neurol. 2017. PMID: 29110780

Arrambide G, Tintore M, Auger C, Río J, Castilló J, Vidal-Jordana A, Galán I, Nos C, Comabella M, Mitjana R, Mulero P, de Barros A, Rodríguez-Acevedo B, Midaglia L, Sastre-Garriga J, Rovira A, Montalban X. Lesion topographies in multiple sclerosis diagnosis: A reappraisal. Neurology. 2017 Dec 5. PMID: 29101276

Tintoré M, Montalban X. The optic nerve should be included as one of the typical CNS regions for establishing dissemination in space when diagnosing MS - No. Mult Scler. 2018 Feb. PMID: 29059000

Martínez-Barriocanal Á, Arcas-García A, Magallon-Lorenz M, Ejarque-Ortíz A, Negro-Demontel ML, Comas-Casellas E, Schwartz S Jr, Malhotra S, Montalban X, Peluffo H, Martín M, Comabella M, Sayós J. Effect of Specific Mutations in Cd300 Complexes Formation; Potential Implication of Cd300f in Multiple Sclerosis. Sci Rep. 2017 Oct 19. PMID: 29051512

Tur C, Montalban X. Progressive MS trials: Lessons learned. Mult Scler. 2017 Oct. PMID: 29041872

Miquel-Serra L, Duarri A, Muñoz Y, Kuebler B, Aran B, Costa C, Martí M, Comabella M, Malhotra S, Montalban X, Veiga A, Raya A. Generation of six multiple sclerosis patient-derived induced pluripotent stem cell lines. Stem Cell Res. 2017 Oct. PMID: 29034884

Alenda R, Costa-Frossard L, Alvarez-Lafuente R, Espejo C, Rodríguez-Martín E, de la Maza SS, Villarrubia N, Río J, Domínguez-Mozo MI, Montalban X, Álvarez-Cermeño JC, Villar LM. Blood lymphocyte subsets identify optimal responders to IFN-beta in MS. J Neurol. 2018 Jan. PMID: 29027004

Sepúlveda M, Aldea M, Escudero D, Llufriu S, Arrambide G, Otero-Romero S, Sastre-Garriga J, Romero-Pinel L, Martínez-Yélamos S, Sola-Valls N, Armangué T, Sotoca J, Escartín A, Robles-Cedeño R, Ramió-Torrentà L, Presas-Rodríguez S, Ramo-Tello C, Munteis E, Pelayo R, Gubieras L, Brieva L, Ortiz N, Hervás M, Mañé-Martínez MA, Cano A, Vela E, Tintoré M, Blanco Y, Montalban X, Graus F, Saiz A. Epidemiology of NMOSD in Catalonia: Influence of the new 2015 criteria in incidence and prevalence estimates. Mult Scler. 2017 Oct 1. PMID: 28984163

Plavina T, Muralidharan KK, Kuesters G, Mikol D, Evans K, Subramanyam M, Nestorov I, Chen Y, Dong Q, Ho PR, Amarante D, Adams A, De Sèze J, Fox R, Gold R, Jeffery D, Kappos L, Montalban X, Weinstock-Guttman B, Hartung HP, Cree BAC. Reversibility of the effects of natalizumab on peripheral immune cell dynamics in MS patients. Neurology. 2017 Oct 10. PMID: 28916537

Saposnik G, Maurino J, Sempere AP, Terzaghi MA, Ruff CC, Mamdani M, Tobler PN, Montalban X. Overcoming Therapeutic Inertia in Multiple Sclerosis Care: A Pilot Randomized Trial Applying the Traffic Light System in Medical Education. Front Neurol. 2017. PMID: 28871238

Bove R, Chitnis T, Cree BA, Tintoré M, Naegelin Y, Uitdehaag BM, Kappos L, Khoury SJ, Montalban X, Hauser SL, Weiner HL, SUMMIT Consortium.. SUMMIT (Serially Unified Multicenter Multiple Sclerosis Investigation): creating a repository of deeply phenotyped contemporary multiple sclerosis cohorts. Mult Scler. 2018 Oct. PMID: 28847219

Preziosa P, Rocca MA, Mesaros S, Meani A, Montalban X, Drulovic J, Droby A, Zipp F, Calabrese M, Sastre-Garriga J, Dujmovic-Basuroski I, Rovira A, Filippi M. Diagnosis of multiple sclerosis: a multicentre study to compare revised McDonald-2010 and Filippi-2010 criteria. J Neurol Neurosurg Psychiatry. 2018 Mar. PMID: 28724720

Fissolo N, Pignolet B, Matute-Blanch C, Triviño JC, Miró B, Mota M, Perez-Hoyos S, Sanchez A, Vermersch P, Ruet A, de Sèze J, Labauge P, Vukusic S, Papeix C, Almoyna L, Tourbah A, Clavelou P, Moreau T, Pelletier J, Lebrun-Frenay C, Montalban X, Brassat D, Comabella M, Biomarkers and Response to Natalizumab for Multiple Sclerosis Treatment (BIONAT), Best EScalation Treatment in Multiple Sclerosis (BEST-MS), and the Société Francophone de la Sclérose En Plaques (SFSEP) Network.. Matrix metalloproteinase 9 is decreased in natalizumab-treated multiple sclerosis patients at risk for progressive multifocal leukoencephalopathy. Ann Neurol. 2017 Aug. PMID: 28681388

Amato MP, Derfuss T, Hemmer B, Liblau R, Montalban X, Soelberg Sørensen P, Miller DH, 2016 ECTRIMS Focused Workshop Group.. Environmental modifiable risk factors for multiple sclerosis: Report from the 2016 ECTRIMS focused workshop. Mult Scler. 2017 Jan 6. PMID: 28671487

Mulero P, Auger C, Parolin L, Fonseca E, Requena M, Rio J, Tintoré M, Rovira A, Montalban X. Varicella-zoster meningovasculitis in a multiple sclerosis patient treated with natalizumab. Mult Scler. 2018 Mar. PMID: 28643544

Rovira A, Auger C, Huerga E, Corral JF, Mitjana R, Sastre-Garriga J, Tintoré M, Montalban X. Cumulative Dose of Macrocyclic Gadolinium-Based Contrast Agent Improves Detection of Enhancing Lesions in Patients with Multiple Sclerosis. AJNR Am J Neuroradiol. 2017 Aug. PMID: 28619842

Miralles M, Eixarch H, Tejero M, Costa C, Hirota K, Castaño AR, Puig M, Stockinger G, Montalban X, Bosch A, Espejo C, Chillon M. Clinical and Histopathological Amelioration of Experimental Autoimmune Encephalomyelitis by AAV Vectors Expressing a Soluble Interleukin-23 Receptor. Neurotherapeutics. 2017 Oct. PMID: 28593439

Fitzgerald KC, Munger KL, Hartung HP, Freedman MS, Montalbán X, Edan G, Wicklein EM, Radue EW, Kappos L, Pohl C, Ascherio A, BENEFIT Study Group.. Sodium intake and multiple sclerosis activity and progression in BENEFIT. Ann Neurol. 2017 Jul. PMID: 28556498

Montalban X, Belachew S, Wolinsky JS. Ocrelizumab in Primary Progressive and Relapsing Multiple Sclerosis. N Engl J Med. 2017 Apr 27. PMID: 28445663

Vidal-Jordana A, Sastre-Garriga J, Pareto D, Tur C, Arrambide G, Otero-Romero S, Huerga E, Mitjana R, Auger C, Tintoré M, Rovira A, Montalban X. Brain atrophy 15 years after CIS: Baseline and follow-up clinico-radiological correlations. Mult Scler. 2018 May. PMID: 28445084

Vidal-Jordana A, Montalban X. Multiple Sclerosis: Epidemiologic, Clinical, and Therapeutic Aspects. Neuroimaging Clin N Am. 2017 May. PMID: 28391781

Arrambide G, Rovira A, Sastre-Garriga J, Tur C, Castilló J, Río J, Vidal-Jordana A, Galán I, Rodríguez-Acevedo B, Midaglia L, Nos C, Mulero P, Arévalo MJ, Comabella M, Huerga E, Auger C, Montalban X, Tintore M. Spinal cord lesions: A modest contributor to diagnosis in clinically isolated syndromes but a relevant prognostic factor. Mult Scler. 2018 Mar. PMID: 28301287

Carrillo-Salinas FJ, Mestre L, Mecha M, Feliú A, Del Campo R, Villarrubia N, Espejo C, Montalbán X, Álvarez-Cermeño JC, Villar LM, Guaza C. Gut dysbiosis and neuroimmune responses to brain infection with Theiler's murine encephalomyelitis virus. Sci Rep. 2017 Mar 14. PMID: 28290524

Río J, Rovira À, Tintoré M, Otero-Romero S, Comabella M, Vidal-Jordana Á, Galán I, Castilló J, Arrambide G, Nos C, Tur C, Pujal B, Auger C, Sastre-Garriga J, Montalban X. Disability progression markers over 6-12 years in interferon-β-treated multiple sclerosis patients. Mult Scler. 2018 Mar. PMID: 28287331

Eixarch H, Calvo-Barreiro L, Montalban X, Espejo C. Bone morphogenetic proteins in multiple sclerosis: Role in neuroinflammation. Brain Behav Immun. 2018 Feb. PMID: 28249802

Sørensen PS, Comi G, Vollmer TL, Montalban X, Kappos L, Dadon Y, Gorfine T, Margalit M, Sasson N, Rubinchick S, Knappertz V. Laquinimod Safety Profile: Pooled Analyses from the ALLEGRO and BRAVO Trials. Int J MS Care. 2017 Jan-Feb. PMID: 28243182

Villoslada P, Alonso C, Agirrezabal I, Kotelnikova E, Zubizarreta I, Pulido-Valdeolivas I, Saiz A, Comabella M, Montalban X, Villar L, Alvarez-Cermeño JC, Fernández O, Alvarez-Lafuente R, Arroyo R, Castro A. Metabolomic signatures associated with disease severity in multiple sclerosis. Neurol Neuroimmunol Neuroinflamm. 2017 Mar. PMID: 28180139

Link J, Ramanujam R, Auer M, Ryner M, Hässler S, Bachelet D, Mbogning C, Warnke C, Buck D, Hyldgaard Jensen PE, Sievers C, Ingenhoven K, Fissolo N, Lindberg R, Grummel V, Donnellan N, Comabella M, Montalban X, Kieseier B, Soelberg Sørensen P, Hartung HP, Derfuss T, Lawton A, Sikkema D, Pallardy M, Hemmer B, Deisenhammer F, Broët P, Dönnes P, Davidson J, Fogdell-Hahn A, ABIRISK Consortium.. Clinical practice of analysis of anti-drug antibodies against interferon beta and natalizumab in multiple sclerosis patients in Europe: A descriptive study of test results. PLoS One. 2017. PMID: 28170401

Trojano M, Tintore M, Montalban X, Hillert J, Kalincik T, Iaffaldano P, Spelman T, Sormani MP, Butzkueven H. Treatment decisions in multiple sclerosis - insights from real-world observational studies. Nat Rev Neurol. 2017 Feb. PMID: 28084327

Matute-Blanch C, Río J, Villar LM, Midaglia L, Malhotra S, Álvarez-Cermeño JC, Vidal-Jordana A, Montalban X, Comabella M. Chitinase 3-like 1 is associated with the response to interferon-beta treatment in multiple sclerosis. J Neuroimmunol. 2017 Feb 15. PMID: 28063616

Montalban X, Hauser SL, Kappos L, Arnold DL, Bar-Or A, Comi G, de Seze J, Giovannoni G, Hartung HP, Hemmer B, Lublin F, Rammohan KW, Selmaj K, Traboulsee A, Sauter A, Masterman D, Fontoura P, Belachew S, Garren H, Mairon N, Chin P, Wolinsky JS, ORATORIO Clinical Investigators.. Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis. N Engl J Med. 2017 Jan 19. PMID: 28002688

Hauser SL, Bar-Or A, Comi G, Giovannoni G, Hartung HP, Hemmer B, Lublin F, Montalban X, Rammohan KW, Selmaj K, Traboulsee A, Wolinsky JS, Arnold DL, Klingelschmitt G, Masterman D, Fontoura P, Belachew S, Chin P, Mairon N, Garren H, Kappos L, OPERA I and OPERA II Clinical Investigators.. Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis. N Engl J Med. 2017 Jan 19. PMID: 28002679

Freedman MS, Montalban X, Miller AE, Dive-Pouletty C, Hass S, Thangavelu K, Leist TP. Comparing outcomes from clinical studies of oral disease-modifying therapies (dimethyl fumarate, fingolimod, and teriflunomide) in relapsing MS: Assessing absolute differences using a number needed to treat analysis. Mult Scler Relat Disord. 2016 Nov. PMID: 27919491

Vidal-Jordana A, Pareto D, Sastre-Garriga J, Auger C, Ciampi E, Montalban X, Rovira A. Measurement of Cortical Thickness and Volume of Subcortical Structures in Multiple Sclerosis: Agreement between 2D Spin-Echo and 3D MPRAGE T1-Weighted Images. AJNR Am J Neuroradiol. 2017 Feb. PMID: 27884876

Lopez de Lapuente A, Feliú A, Ugidos N, Mecha M, Mena J, Astobiza I, Riera J, Carrillo-Salinas FJ, Comabella M, Montalban X, Alloza I, Guaza C, Vandenbroeck K. Correction: Novel Insights into the Multiple Sclerosis Risk Gene ANKRD55. J Immunol. 2016 Nov 15. PMID: 27815448

Casacuberta-Serra S, Costa C, Eixarch H, Mansilla MJ, López-Estévez S, Martorell L, Parés M, Montalban X, Espejo C, Barquinero J. Myeloid-derived suppressor cells expressing a self-antigen ameliorate experimental autoimmune encephalomyelitis. Exp Neurol. 2016 Dec. PMID: 27693617

Gutiérrez-Franco A, Eixarch H, Costa C, Gil V, Castillo M, Calvo-Barreiro L, Montalban X, Del Río JA, Espejo C. Semaphorin 7A as a Potential Therapeutic Target for Multiple Sclerosis. Mol Neurobiol. 2017 Aug. PMID: 27714632

Órpez-Zafra T, Pavía J, Hurtado-Guerrero I, Pinto-Medel MJ, Rodriguez Bada JL, Urbaneja P, Suardíaz M, Villar LM, Comabella M, Montalban X, Alvarez-Cermeño JC, Leyva L, Fernández Ó, Oliver-Martos B. Decreased soluble IFN-β receptor (sIFNAR2) in multiple sclerosis patients: A potential serum diagnostic biomarker. Mult Scler. 2017 Jun. PMID: 27613121

Tintore M, Otero-Romero S, Río J, Arrambide G, Pujal B, Tur C, Galán I, Comabella M, Nos C, Arévalo MJ, Vidal-Jordana A, Castilló J, Rodríguez-Acevedo B, Midaglia L, Mitjana R, Auger C, Sastre-Garriga J, Rovira À, Montalban X. Contribution of the symptomatic lesion in establishing MS diagnosis and prognosis. Neurology. 2016 Sep 27. PMID: 27566747

Arrambide G, Espejo C, Eixarch H, Villar LM, Alvarez-Cermeño JC, Picón C, Kuhle J, Disanto G, Kappos L, Sastre-Garriga J, Pareto D, Simon E, Comabella M, Río J, Nos C, Tur C, Castilló J, Vidal-Jordana A, Galán I, Arévalo MJ, Auger C, Rovira A, Montalban X, Tintore M. Neurofilament light chain level is a weak risk factor for the development of MS. Neurology. 2016 Sep 13. PMID: 27521440

Kappos L, Edan G, Freedman MS, Montalbán X, Hartung HP, Hemmer B, Fox EJ, Barkhof F, Schippling S, Schulze A, Pleimes D, Pohl C, Sandbrink R, Suarez G, Wicklein EM, BENEFIT Study Group.. The 11-year long-term follow-up study from the randomized BENEFIT CIS trial. Neurology. 2016 Sep 6. PMID: 27511182

Gold R, Radue EW, Giovannoni G, Selmaj K, Havrdova E, Stefoski D, Sprenger T, Montalban X, Cohan S, Umans K, Greenberg SJ, Ozen G, Elkins J. Safety and efficacy of daclizumab in relapsing-remitting multiple sclerosis: 3-year results from the SELECTED open-label extension study. BMC Neurol. 2016 Jul 26. PMID: 27461166

Aymerich FX, Auger C, Alcaide-Leon P, Pareto D, Huerga E, Corral JF, Mitjana R, Sastre-Garriga J, Montalban X, Rovira A. Comparison between gadolinium-enhanced 2D T1-weighted gradient-echo and spin-echo sequences in the detection of active multiple sclerosis lesions on 3.0T MRI. Eur Radiol. 2017 Apr. PMID: 27456965

Rio J, Rovira A, Blanco Y, Sainz A, Perkal H, Robles R, Ramio-Torrenta L, Diaz RM, Arroyo R, Urbaneja P, Fernandez O, Garcia-Merino JA, Reyes MP, Oreja-Guevara C, Prieto JM, Izquierdo G, Olascoaga J, Alvarez-Cermeno JC, Simon E, Pujal B, Comabella M, Montalban X. [Response to treatment with interferon beta in patients with multiple sclerosis. Validation of the Rio Score]. Rev Neurol. 2016 Aug 16. PMID: 27439483

Kappos L, Li DK, Stüve O, Hartung HP, Freedman MS, Hemmer B, Rieckmann P, Montalban X, Ziemssen T, Hunter B, Arnould S, Wallström E, Selmaj K. Safety and Efficacy of Siponimod (BAF312) in Patients With Relapsing-Remitting Multiple Sclerosis: Dose-Blinded, Randomized Extension of the Phase 2 BOLD Study. JAMA Neurol. 2016 Sep 1. PMID: 27380540

Ciampi E, Pareto D, Sastre-Garriga J, Vidal-Jordana A, Tur C, Río J, Tintoré M, Auger C, Rovira A, Montalban X. Grey matter atrophy is associated with disability increase in natalizumab-treated patients. Mult Scler. 2017 Apr. PMID: 27354019

Sormani MP, Gasperini C, Romeo M, Rio J, Calabrese M, Cocco E, Enzingher C, Fazekas F, Filippi M, Gallo A, Kappos L, Marrosu MG, Martinelli V, Prosperini L, Rocca MA, Rovira A, Sprenger T, Stromillo ML, Tedeschi G, Tintorè M, Tortorella C, Trojano M, Montalban X, Pozzilli C, Comi G, De Stefano N, MAGNIMS study group.. Assessing response to interferon-β in a multicenter dataset of patients with MS. Neurology. 2016 Jul 12. PMID: 27306626

Cabezas M, Corral JF, Oliver A, Díez Y, Tintoré M, Auger C, Montalban X, Lladó X, Pareto D, Rovira À. Improved Automatic Detection of New T2 Lesions in Multiple Sclerosis Using Deformation Fields. AJNR Am J Neuroradiol. 2016 Oct. PMID: 27282863

Fernandez O, Rodriguez-Antiguedad A, Olascoaga J, Oreja-Guevara C, Prieto JM, Mendibe-Bilbao MM, Garcia-Merino JA, Ramio-Torrenta L, Ginestal R, Meca-Lallana JE, Romero-Pinel L, Munoz D, Saiz A, Calles-Hernandez MC, Izquierdo G, Villar LM, Oliva-Nacarino P, Arnal-Garcia C, Comabella M, Brieva L, Arroyo R, Montalban X. Review of the novelties from the 31st ECTRIMS Congress, 2015, presented at the 8th Post-ECTRIMS meeting. Rev Neurol. 2016 Jun 16. PMID: 27270678

Otero-Romero S, Sastre-Garriga J, Comi G, Hartung HP, Soelberg Sørensen P, Thompson AJ, Vermersch P, Gold R, Montalban X. Pharmacological management of spasticity in multiple sclerosis: Systematic review and consensus paper. Mult Scler. 2016 Oct. PMID: 27207462

Sadovnick AD, Traboulsee AL, Bernales CQ, Ross JP, Forwell AL, Yee IM, Guillot-Noel L, Fontaine B, Cournu-Rebeix I, Alcina A, Fedetz M, Izquierdo G, Matesanz F, Hilven K, Dubois B, Goris A, Astobiza I, Alloza I, Antigüedad A, Vandenbroeck K, Akkad DA, Aktas O, Blaschke P, Buttmann M, Chan A, Epplen JT, Gerdes LA, Kroner A, Kubisch C, Kümpfel T, Lohse P, Rieckmann P, Zettl UK, Zipp F, Bertram L, Lill CM, Fernandez O, Urbaneja P, Leyva L, Alvarez-Cermeño JC, Arroyo R, Garagorri AM, García-Martínez A, Villar LM, Urcelay E, Malhotra S, Montalban X, Comabella M, Berger T, Fazekas F, Reindl M, Schmied MC, Zimprich A, Vilariño-Güell C. Analysis of Plasminogen Genetic Variants in Multiple Sclerosis Patients. G3 (Bethesda). 2016 Jul 7. PMID: 27194806

Lopez de Lapuente A, Feliú A, Ugidos N, Mecha M, Mena J, Astobiza I, Riera J, Carrillo-Salinas FJ, Comabella M, Montalban X, Alloza I, Guaza C, Vandenbroeck K. Novel Insights into the Multiple Sclerosis Risk Gene ANKRD55. J Immunol. 2016 Jun 1. PMID: 27183579

Sepúlveda M, Armangue T, Martinez-Hernandez E, Arrambide G, Sola-Valls N, Sabater L, Téllez N, Midaglia L, Ariño H, Peschl P, Reindl M, Rovira A, Montalban X, Blanco Y, Dalmau J, Graus F, Saiz A. Clinical spectrum associated with MOG autoimmunity in adults: significance of sharing rodent MOG epitopes. J Neurol. 2016 Jul. PMID: 27147513

Sepúlveda M, Armangué T, Sola-Valls N, Arrambide G, Meca-Lallana JE, Oreja-Guevara C, Mendibe M, Alvarez de Arcaya A, Aladro Y, Casanova B, Olascoaga J, Jiménez-Huete A, Fernández-Fournier M, Ramió-Torrentà L, Cobo-Calvo A, Viñals M, de Andrés C, Meca-Lallana V, Cervelló A, Calles C, Rubio MB, Ramo-Tello C, Caminero A, Munteis E, Antigüedad AR, Blanco Y, Villoslada P, Montalban X, Graus F, Saiz A. Neuromyelitis optica spectrum disorders: Comparison according to the phenotype and serostatus. Neurol Neuroimmunol Neuroinflamm. 2016 Jun. PMID: 27144216

Waters P, Reindl M, Saiz A, Schanda K, Tuller F, Kral V, Nytrova P, Sobek O, Nielsen HH, Barington T, Lillevang ST, Illes Z, Rentzsch K, Berthele A, Berki T, Granieri L, Bertolotto A, Giometto B, Zuliani L, Hamann D, van Pelt ED, Hintzen R, Höftberger R, Costa C, Comabella M, Montalban X, Tintoré M, Siva A, Altintas A, Deniz G, Woodhall M, Palace J, Paul F, Hartung HP, Aktas O, Jarius S, Wildemann B, Vedeler C, Ruiz A, Leite MI, Trillenberg P, Probst M, Saschenbrecker S, Vincent A, Marignier R. Multicentre comparison of a diagnostic assay: aquaporin-4 antibodies in neuromyelitis optica. J Neurol Neurosurg Psychiatry. 2016 Sep. PMID: 27113605

Comabella M, Sastre-Garriga J, Montalban X. Precision medicine in multiple sclerosis: biomarkers for diagnosis, prognosis, and treatment response. Curr Opin Neurol. 2016 Jun. PMID: 27075495

Keshavan A, Paul F, Beyer MK, Zhu AH, Papinutto N, Shinohara RT, Stern W, Amann M, Bakshi R, Bischof A, Carriero A, Comabella M, Crane JC, D'Alfonso S, Demaerel P, Dubois B, Filippi M, Fleischer V, Fontaine B, Gaetano L, Goris A, Graetz C, Gröger A, Groppa S, Hafler DA, Harbo HF, Hemmer B, Jordan K, Kappos L, Kirkish G, Llufriu S, Magon S, Martinelli-Boneschi F, McCauley JL, Montalban X, Mühlau M, Pelletier D, Pattany PM, Pericak-Vance M, Cournu-Rebeix I, Rocca MA, Rovira A, Schlaeger R, Saiz A, Sprenger T, Stecco A, Uitdehaag BMJ, Villoslada P, Wattjes MP, Weiner H, Wuerfel J, Zimmer C, Zipp F, International Multiple Sclerosis Genetics Consortium. Electronic address: AIVINSON@PARTNERS.ORG., Hauser SL, Oksenberg JR, Henry RG. Power estimation for non-standardized multisite studies. Neuroimage. 2016 Jul 1. PMID: 27039700

Mahurkar S, Moldovan M, Suppiah V, Sorosina M, Clarelli F, Liberatore G, Malhotra S, Montalban X, Antigüedad A, Krupa M, Jokubaitis VG, McKay FC, Gatt PN, Fabis-Pedrini MJ, Martinelli V, Comi G, Lechner-Scott J, Kermode AG, Slee M, Taylor BV, Vandenbroeck K, Comabella M, Boneschi FM, Australian and New Zealand Multiple Sclerosis Genetics Consortium (ANZgene)., King C. Response to interferon-beta treatment in multiple sclerosis patients: a genome-wide association study. Pharmacogenomics J. 2017 Jul. PMID: 27001119

Midaglia L, Juega Mariño JM, Sastre-Garriga J, Rovira A, Vidal-Jordana A, López-Pérez MA, Marzo-Sola ME, Librada Escribano F, Montalban X. An uncommon first manifestation of multiple sclerosis: Tako-Tsubo cardiomyopathy. Mult Scler. 2016 May. PMID: 26993120

Vidal-Jordana A, Sastre-Garriga J, Pérez-Miralles F, Pareto D, Rio J, Auger C, Tintoré M, Rovira A, Montalban X. Brain Volume Loss During the First Year of Interferon-Beta Treatment in Multiple Sclerosis: Baseline Inflammation and Regional Brain Volume Dynamics. J Neuroimaging. 2016 Sep. PMID: 26935253

Hegen H, Adrianto I, Lessard CJ, Millonig A, Bertolotto A, Comabella M, Giovannoni G, Guger M, Hoelzl M, Khalil M, Fazekas F, Killestein J, Lindberg RL, Malucchi S, Mehling M, Montalban X, Rudzki D, Schautzer F, Sellebjerg F, Sorensen PS, Deisenhammer F, Steinman L, Axtell RC. Cytokine profiles show heterogeneity of interferon-β response in multiple sclerosis patients. Neurol Neuroimmunol Neuroinflamm. 2016 Apr. PMID: 26894205

Pareto D, Sastre-Garriga J, Aymerich FX, Auger C, Tintoré M, Montalban X, Rovira A. Lesion filling effect in regional brain volume estimations: a study in multiple sclerosis patients with low lesion load. Neuroradiology. 2016 May. PMID: 26847633

Lublin F, Miller DH, Freedman MS, Cree BAC, Wolinsky JS, Weiner H, Lubetzki C, Hartung HP, Montalban X, Uitdehaag BMJ, Merschhemke M, Li B, Putzki N, Liu FC, Häring DA, Kappos L, INFORMS study investigators.. Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet. 2016 Mar 12. PMID: 26827074

Filippi M, Rocca MA, Ciccarelli O, De Stefano N, Evangelou N, Kappos L, Rovira A, Sastre-Garriga J, Tintorè M, Frederiksen JL, Gasperini C, Palace J, Reich DS, Banwell B, Montalban X, Barkhof F, MAGNIMS Study Group.. MRI criteria for the diagnosis of multiple sclerosis: MAGNIMS consensus guidelines. Lancet Neurol. 2016 Mar. PMID: 26822746

Valverde S, Oliver A, Roura E, Pareto D, Vilanova JC, Ramió-Torrentà L, Sastre-Garriga J, Montalban X, Rovira À, Lladó X. Quantifying brain tissue volume in multiple sclerosis with automated lesion segmentation and filling. Neuroimage Clin. 2015. PMID: 26740917